×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
3SBio Subsidiary Strikes Key Weight Management Drug Deal - TipRanks.com
Tipranks
3SBio (HK:1530) has released an update. 3SBio Inc.'s subsidiary, Sunshine Mandi, has inked a lucrative cooperation agreement with Hybio Pharmaceutical for...
5 days ago
There's Reason For Concern Over 3SBio Inc.'s (HKG:1530) Price
Simply Wall Street
With a median price-to-earnings (or "P/E") ratio of close to 10x in Hong Kong, you could be forgiven for feeling indifferent about 3SBio...
2 weeks ago
3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly ...
PR Newswire
Share this article ... HONG KONG, Aug. 24, 2023 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its 2023...
9 months ago
3SBio Inc. Schedules Annual General Meeting
TipRanks
3SBio (HK:1530) has released an update. 3SBio Inc. has announced its annual general meeting to be held on June 25, 2024, where shareholders will review the...
1 week ago
《AI》3SBIO(01530.HK) Displays Technical Pattern of Death Cross
AASTOCKS.com
3SBIO(01530.HK)'s SMA 10 crosses below SMA 20, which is a death cross. Last printed at 6.090; fell 2.090%; on volume of 1.90M shares and...
1 week ago
Best Under A Billion 2018: China Drugmaker Struggles To Break Into Europe And North America
Forbes
Lou Jing's drugmaker has gotten a big foothold in China and wants future breakthroughs to be global.
70 months ago
3SBio, Verseau Establish Immuno-Oncology Devt. Collaboration
Contract Pharma
3SBio, Verseau Establish Immuno-Oncology Devt. Collaboration ... 3SBio and Verseau Therapeutics have formed a partnership to develop and...
55 months ago
3Sbio licenses out global rights of PD-1 inhibitor to Syncromune
BioWorld MedTech
3Sbio Inc.'s subsidiary, Sunshine Guojian Pharmaceutical Co. Ltd., has licensed out the global rights of its anti-PD-1 antibody candidate,...
28 months ago
Interferons Market size is set to grow by USD 2.65 bn from 2024-2028, 3SBio Inc., Bayer AG & Biogen Inc., and more to ...
PR Newswire
Notably, SNG001, a new interferon beta-1a treatment, has recently received regulatory approval. The market's expansion is further fueled by the...
2 months ago
AZ taps 3SBio to help drive sales of diabetes meds Byetta, Bydureon in China
Fierce Pharma
AZ is signing over commercial rights in China to its GLP-1 agonist Byetta (exenatide) and long-acting version Bydureon for $50 million up front,...
91 months ago